Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pasireotide - RECORDATI

Drug Profile

Pasireotide - RECORDATI

Alternative Names: Pashireochidopamo salt; pasireotide LAR; Pasireotide pamoate; SIGNIFOR; SIGNIFOR LAR; SOM 230; SOM 230 LAR; SOM230C

Latest Information Update: 13 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis; UNC Lineberger Comprehensive Cancer Center; University of Arkansas for Medical Sciences; University of Miami
  • Class Analgesics; Antineoplastics; Antisecretories; Cyclic peptides; Macrocyclic compounds; Oligopeptides; Peptidomimetics
  • Mechanism of Action Corticotropin releasing hormone inhibitors; Growth hormone-releasing hormone inhibitors; Insulin-like growth factor I inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pituitary ACTH hypersecretion; Neuroendocrine tumours; Acromegaly
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly; Gigantism; Pituitary ACTH hypersecretion
  • Phase II Cluster headache; Pituitary cancer
  • Discontinued Carcinoid tumour; Gastrointestinal cancer; Gastrointestinal disorders; Liver cancer; Malignant melanoma; Meningioma; Merkel cell carcinoma; Neuroendocrine tumours; Pancreatic cancer; Pancreatic disorders; Prostate cancer; Radiation injuries; Uveal melanoma

Most Recent Events

  • 02 Mar 2023 H. Lee Moffitt Cancer Center and Research Institute in collaboration with Novartis and Recordati complete a phase II trial for Neuroendocrine tumours (Metastatic disease; Inoperable/Unresectable) in the US (IM) (NCT01253161)
  • 27 Apr 2022 No development reported - Phase-II for Pituitary ACTH Hypersecretion (Monotherapy; Combination therapy) in Australia, Belgium, Brazil, Bulgaria, Colombia, Greece, Germany, Hungary, India, Italy, Malaysia, Mexico, Spain (SC)
  • 04 Jun 2021 Long-term efficacy and adverse event data from the phase II LUNA trial in Neuroendocrine carcinoma presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top